ECSP12012352A - Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal - Google Patents
Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renalInfo
- Publication number
- ECSP12012352A ECSP12012352A ECSP12012352A ECSP12012352A EC SP12012352 A ECSP12012352 A EC SP12012352A EC SP12012352 A ECSP12012352 A EC SP12012352A EC SP12012352 A ECSP12012352 A EC SP12012352A
- Authority
- EC
- Ecuador
- Prior art keywords
- hypertension
- renal dysfunction
- therapeutic agent
- sustained release
- release therapeutic
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title abstract 5
- 230000008085 renal dysfunction Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- -1 2-phenylthiazole compound Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención da a conocer un agente terapéutico o preventivo para la hipertensión o la presión sanguínea alta normal, y para la disfunción renal, que es más eficaz que las drogas existentes.Más específicamente, la presente invención da a conocer una composición farmacéutica de liberación sostenida para el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal, y para la disfunción renal, que comprende, como ingrediente activo, un compuesto de 2-feniltiazol representado por la siguiente fórmula (I)Fórmula química 1 (I)o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010145056 | 2010-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012352A true ECSP12012352A (es) | 2013-02-28 |
Family
ID=45371556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012352 ECSP12012352A (es) | 2010-06-25 | 2012-12-20 | Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20130109726A1 (es) |
| EP (1) | EP2586442A4 (es) |
| JP (1) | JPWO2011162390A1 (es) |
| KR (1) | KR20130088755A (es) |
| CN (1) | CN102958521A (es) |
| AR (1) | AR082022A1 (es) |
| AU (1) | AU2011270133B2 (es) |
| BR (1) | BR112012032543A2 (es) |
| CA (1) | CA2803163A1 (es) |
| CL (1) | CL2012003661A1 (es) |
| CO (1) | CO6660504A2 (es) |
| EC (1) | ECSP12012352A (es) |
| MA (1) | MA34328B1 (es) |
| MX (1) | MX2012015040A (es) |
| MY (1) | MY160963A (es) |
| NZ (1) | NZ605516A (es) |
| PE (1) | PE20130241A1 (es) |
| PH (1) | PH12012502487A1 (es) |
| RU (1) | RU2013103366A (es) |
| SG (1) | SG186798A1 (es) |
| TN (1) | TN2012000568A1 (es) |
| TW (1) | TW201215389A (es) |
| UA (1) | UA107716C2 (es) |
| UY (1) | UY33468A (es) |
| WO (1) | WO2011162390A1 (es) |
| ZA (1) | ZA201209388B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2582812B1 (en) | 2010-06-16 | 2018-01-24 | Takeda Pharmaceuticals U.S.A., Inc. | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
| JP5978216B2 (ja) | 2010-09-10 | 2016-08-24 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | テオフィリンとフェブキソスタットの併用療法のための方法 |
| WO2013111870A1 (ja) * | 2012-01-27 | 2013-08-01 | 帝人ファーマ株式会社 | 糖尿病の治療薬 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2073981C (en) | 1990-11-30 | 2002-01-08 | Shiro Kondo | 2-arylthiazole derivatives and pharmaceutical composition thereof |
| US6998404B2 (en) * | 2001-08-08 | 2006-02-14 | Genomed, Llc | Treatment or prevention of acute renal failure |
| WO2007019153A2 (en) | 2005-08-03 | 2007-02-15 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
| CN101291656B (zh) * | 2005-08-18 | 2012-11-07 | 帝人制药株式会社 | 具有准确的用量分割功能的制剂 |
| CA2669935A1 (en) * | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America, Inc. | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
| CN101658505A (zh) * | 2009-09-29 | 2010-03-03 | 北京华禧联合科技发展有限公司 | 非布索坦的缓释制剂及其制备方法 |
| EP2582812B1 (en) * | 2010-06-16 | 2018-01-24 | Takeda Pharmaceuticals U.S.A., Inc. | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
-
2011
- 2011-06-24 AR ARP110102214A patent/AR082022A1/es unknown
- 2011-06-24 KR KR1020127033036A patent/KR20130088755A/ko not_active Withdrawn
- 2011-06-24 JP JP2012521553A patent/JPWO2011162390A1/ja not_active Ceased
- 2011-06-24 EP EP11798271.0A patent/EP2586442A4/en not_active Withdrawn
- 2011-06-24 TW TW100122222A patent/TW201215389A/zh unknown
- 2011-06-24 MX MX2012015040A patent/MX2012015040A/es not_active Application Discontinuation
- 2011-06-24 BR BR112012032543A patent/BR112012032543A2/pt not_active IP Right Cessation
- 2011-06-24 CA CA2803163A patent/CA2803163A1/en not_active Abandoned
- 2011-06-24 PE PE2012002449A patent/PE20130241A1/es not_active Application Discontinuation
- 2011-06-24 PH PH1/2012/502487A patent/PH12012502487A1/en unknown
- 2011-06-24 RU RU2013103366/15A patent/RU2013103366A/ru unknown
- 2011-06-24 SG SG2012094645A patent/SG186798A1/en unknown
- 2011-06-24 MA MA35480A patent/MA34328B1/fr unknown
- 2011-06-24 WO PCT/JP2011/064569 patent/WO2011162390A1/ja not_active Ceased
- 2011-06-24 UY UY0001033468A patent/UY33468A/es not_active Application Discontinuation
- 2011-06-24 MY MYPI2012701137A patent/MY160963A/en unknown
- 2011-06-24 CN CN2011800311202A patent/CN102958521A/zh active Pending
- 2011-06-24 US US13/806,370 patent/US20130109726A1/en not_active Abandoned
- 2011-06-24 NZ NZ605516A patent/NZ605516A/en not_active IP Right Cessation
- 2011-06-24 UA UAA201300872A patent/UA107716C2/ru unknown
- 2011-06-24 AU AU2011270133A patent/AU2011270133B2/en not_active Ceased
-
2012
- 2012-11-30 TN TNP2012000568A patent/TN2012000568A1/en unknown
- 2012-12-11 ZA ZA2012/09388A patent/ZA201209388B/en unknown
- 2012-12-20 EC ECSP12012352 patent/ECSP12012352A/es unknown
- 2012-12-20 CO CO12230952A patent/CO6660504A2/es unknown
- 2012-12-21 CL CL2012003661A patent/CL2012003661A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2586442A4 (en) | 2014-01-01 |
| WO2011162390A1 (ja) | 2011-12-29 |
| CA2803163A1 (en) | 2011-12-29 |
| ZA201209388B (en) | 2013-08-28 |
| BR112012032543A2 (pt) | 2016-11-22 |
| JPWO2011162390A1 (ja) | 2013-08-22 |
| CN102958521A (zh) | 2013-03-06 |
| EP2586442A1 (en) | 2013-05-01 |
| SG186798A1 (en) | 2013-02-28 |
| AR082022A1 (es) | 2012-11-07 |
| PE20130241A1 (es) | 2013-03-04 |
| TN2012000568A1 (en) | 2014-04-01 |
| TW201215389A (en) | 2012-04-16 |
| AU2011270133B2 (en) | 2014-03-20 |
| MY160963A (en) | 2017-03-31 |
| AU2011270133A1 (en) | 2013-01-10 |
| UA107716C2 (ru) | 2015-02-10 |
| UY33468A (es) | 2012-01-31 |
| PH12012502487A1 (en) | 2017-08-09 |
| RU2013103366A (ru) | 2014-07-27 |
| MA34328B1 (fr) | 2013-06-01 |
| CL2012003661A1 (es) | 2013-04-01 |
| MX2012015040A (es) | 2013-02-07 |
| CO6660504A2 (es) | 2013-04-30 |
| US20130109726A1 (en) | 2013-05-02 |
| NZ605516A (en) | 2015-02-27 |
| KR20130088755A (ko) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| JO3530B1 (ar) | مركبات بيريدازين 1،4-ثنائية الإرتباط ونظائرها وطرق معالجة نقص smn وحالاته المرضية. | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| MY161001A (en) | Tetrahydrocarboline Derivative | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| ECSP13012812A (es) | Formulaciones inmunosupresoras | |
| CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| CO6660504A2 (es) | Agente terapeutico de liberacion sostenida para la hipertensión y la disfunción renal | |
| CO6290762A2 (es) | Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral | |
| BR112012024346A2 (pt) | agente terapêutico ou agente profilático para a doença de alzheimer | |
| PE20130308A1 (es) | Metodos para tratar infecciones bacterianas recurrentes | |
| AR083780A1 (es) | Composicion farmaceutica para tratar infecciones del hcv | |
| BR112012020415A2 (pt) | composição farmacêutica para a prevenção ou tratamento da osteoartrite | |
| ECSP099733A (es) | Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias | |
| WO2010027189A3 (ko) | 호모아이소플라베논 또는 이의 염의 신규한 용도 |